{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Estimated by the number of sCRs divided by the total number of evaluable patients in each arm. Exact binomial confidence intervals for the true sCR rate will be calculated by arm. Stringent complete response (sCR) is defined as a complete response plus normal serum free light chain ratio and the absence of clonal cells in bone marrow by flow cytometry.","groups":[{"description":"Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.","id":"OG000","title":"Arm A"},{"description":"Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.","id":"OG001","title":"Arm B"},{"description":"Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.","id":"OG002","title":"Arm C"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}